Type 1 Plasminogen Deficiency With Pulmonary Involvement: Novel Treatment and Novel Mutation
Melih Hangul1, Ahmet B Tuzuner2, Ido Somekh3
1Departments of Child Chest Diseases.
Abstract:
Type 1 plasminogen deficiency is a rare genetic disorder. Type 1 plasminogen deficiency is characterized by fibrin-rich pseudomembrane formation on mucosal surfaces, particularly the conjunctiva. Tracheobronchial tree involvement is a less common reported manifestation of type 1 plasminogen deficiency. Pseudomembranes in the tracheobronchial tree may result in respiratory compromise and ultimately fail if not recognized and treated. Currently, there is no specific replacement therapy approved for the treatment of congenital plasminogen deficiency. In the present paper, we report that type 1 plasminogen deficiency with novel frameshift mutation and pulmonary involvement was treated initially with systemic fresh frozen plasma followed by pulmonary lavage with fresh frozen plasma and tissue plasminogen activator.
Insights
Type 1 plasminogen deficiency, a rare genetic disorder, can affect the lungs. This study details a novel treatment approach using fresh frozen plasma for pulmonary pseudomembranes.
Area of Science:
- Genetics
- Pulmonology
- Hematology
Background:
- Type 1 plasminogen deficiency is a rare genetic disorder.
- It typically presents with fibrin-rich pseudomembranes on mucosal surfaces, such as the conjunctiva.
- Pulmonary involvement, though less common, can lead to severe respiratory compromise.
Related Concept Videos
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Pulmonary Hypertension: Classification and Pathogenesis
There are various classifications for PH, each relating to different underlying causes and also...
Venous Thrombosis III: Interprofessional Care
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...


